INSM:NGS-Insmed Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 70

Change

0.00 (0.00)%

Market Cap

USD 0.88B

Volume

4.14M

Analyst Target

USD 45.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insmed Inc is a biopharmaceutical company. The Company is developing ARIKAYCE for inhalation (LAI), for patients with nontuberculous mycobacteria lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.76 (+0.39%)

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

-1.77 (-0.17%)

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

-1.54 (-0.57%)

USD 34.86B
ARGX argenx NV ADR

-13.04 (-2.40%)

USD 32.89B
MRNA Moderna Inc

-0.87 (-1.42%)

USD 25.27B
BGNE BeiGene Ltd

+12.40 (+5.31%)

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

+5.86 (+1.67%)

USD 15.95B
SMMT Summit Therapeutics PLC

+0.48 (+2.58%)

USD 15.35B
PCVX Vaxcyte Inc

+0.21 (+0.19%)

USD 14.00B

ETFs Containing INSM

PTH Invesco DWA Healthcare Mo.. 4.50 % 0.60 %

+0.37 (+1.45%)

USD 0.15B
FCUS Pinnacle Focused Opportun.. 3.94 % 0.00 %

+0.41 (+1.45%)

USD 0.03B
LABU Direxion Daily S&P Biotec.. 1.66 % 1.14 %

+2.94 (+1.45%)

USD 0.94B
VTWG Vanguard Russell 2000 Gro.. 0.88 % 0.20 %

+3.48 (+1.45%)

USD 1.02B
BBSC JPMorgan BetaBuilders U.S.. 0.79 % 0.00 %

+1.01 (+1.45%)

USD 0.53B
XRS2:SW Xtrackers Russell 2000 UC.. 0.45 % 0.00 %

+5.60 (+1.45%)

USD 1.38B
RSSL Global X Funds 0.45 % 0.00 %

+1.23 (+1.45%)

N/A
R2US:SW SPDR® Russell 2000 US Sm.. 0.45 % 0.00 %

+0.93 (+1.45%)

USD 3.30B
VTWO Vanguard Russell 2000 Ind.. 0.44 % 0.15 %

+1.23 (+1.45%)

USD 11.71B
UWM ProShares Ultra Russell20.. 0.35 % 0.95 %

+1.13 (+1.45%)

USD 0.29B
HDG ProShares Hedge Replicati.. 0.00 % 0.95 %

+0.20 (+1.45%)

USD 0.03B
IWM iShares Russell 2000 ETF 0.00 % 0.19 %

+3.02 (+1.45%)

N/A
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

+4.68 (+1.45%)

N/A
JKJ 0.00 % 0.25 %

N/A

N/A
JKK 0.00 % 0.30 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

N/A

USD 1.19B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.00 %

+5.01 (+1.45%)

USD 10.02B
SCHA Schwab U.S. Small-Cap ETF 0.00 % 0.05 %

+0.66 (+1.45%)

USD 17.80B
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

+2.09 (+1.45%)

USD 0.46B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

+0.45 (+1.45%)

USD 3.31B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

+0.52 (+1.45%)

USD 3.31B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

+212.50 (+1.45%)

USD 1.38B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

+2.48 (+1.45%)

USD 1.38B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

+0.77 (+1.45%)

USD 3.34B
XRS2:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

N/A

USD 1.19B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 2.91B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

+3.60 (+1.45%)

USD 1.19B
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

+0.78 (+1.45%)

USD 2.91B
ISCG iShares Morningstar Small.. 0.00 % 0.00 %

+0.65 (+1.45%)

USD 0.61B
ISCB iShares Morningstar Small.. 0.00 % 0.00 %

+0.72 (+1.45%)

USD 0.23B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 125.88% 94% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 125.88% 94% A 97% N/A
Trailing 12 Months  
Capital Gain 252.47% 99% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 252.47% 99% N/A 99% N/A
Trailing 5 Years  
Capital Gain 197.37% 90% A- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 197.37% 90% A- 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 39.04% 84% B 88% B+
Dividend Return 39.04% 83% B 88% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 358.65% 9% A- 5% F
Risk Adjusted Return 10.89% 69% C- 48% F
Market Capitalization 0.88B 98% N/A 93% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 25.45 6% 4%
Price / Cash Flow Ratio -20.18 91% 88%
Price/Free Cash Flow Ratio -6.78 79% 80%
Management Effectiveness  
Return on Equity -1,453.41% 5% 2%
Return on Invested Capital -69.94% 43% 17%
Return on Assets -31.79% 49% 17%
Debt to Equity Ratio -348.07% 96% 97%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector